Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

Brogan, Anita J

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. [electronic resource] - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 657-64 p. digital

Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't

1524-4733

10.1016/j.jval.2011.01.009 doi


Adenine--analogs & derivatives
Adult
Alkynes
Anti-HIV Agents--economics
Antiretroviral Therapy, Highly Active
Benzoxazines--economics
CD4 Lymphocyte Count
Clinical Trials as Topic
Cost Savings
Cost-Benefit Analysis
Cyclopropanes
Deoxycytidine--analogs & derivatives
Dideoxynucleosides--economics
Drug Costs
Emtricitabine
Female
HIV Infections--diagnosis
Health Services Research
Humans
Lamivudine--economics
Male
Markov Chains
Models, Economic
Organophosphonates--economics
Outcome and Process Assessment, Health Care--economics
Quality-Adjusted Life Years
Reverse Transcriptase Inhibitors--economics
Tenofovir
Time Factors
Treatment Outcome
United States--epidemiology
Viral Load
Zidovudine--economics